HighTower Advisors’s Fulgent Genetics FLGT Stock Holding History

HighTower Advisors’s Portfolio FLGT Stock Details FLGT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-5,784	Closed	-$213K	–	3632
2023 Q2	$213K	Buy	+5,784	New	+$202K	﹤0.01%	2814
2023 Q1	–	Sell	-8,800	Closed	-$264K	–	3506
2022 Q4	$264K	Buy	8,800 +1,386	+19%	+$49.6K	﹤0.01%	2564
2022 Q3	$279K	Sell	7,414 -217	-3%	-$10.9K	﹤0.01%	2390
2022 Q2	$413K	Sell	7,631 -47	-0.6%	-$2.58K	﹤0.01%	2162
2022 Q1	$476K	Buy	7,678 +87	+1%	+$5.73K	﹤0.01%	2206
2021 Q4	$770K	Buy	7,591 +3,699	+95%	+$325K	﹤0.01%	1909
2021 Q3	$349K	Sell	3,892 -938	-19%	-$85.3K	﹤0.01%	2315
2021 Q2	$446K	Sell	4,830 -820	-15%	-$65.5K	﹤0.01%	2116
2021 Q1	$545K	Sell	5,650 -1,936	-26%	-$200K	﹤0.01%	1922
2020 Q4	$395K	Buy	+7,586	New	+$317K	﹤0.01%	1753

Other funds holding FLGT

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

DSCM

Divisadero Street Capital Management Miami, Florida $2.39B AUM 134.55% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

PWAM

Park West Asset Management San Francisco, California $1.18B AUM 47.25% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

HighTower Advisors's FLGT Position: Q3 2023 in Review

HighTower Advisors sold out of Fulgent Genetics (FLGT) in Q3 2023, closing a stake of 5,784 shares — an estimated $213K sold.

HighTower Advisors first reported a position in FLGT in Q4 2020 and held it in 10 quarters. The position peaked at $770K in Q4 2021. 201 funds tracked by Wall St. Rank hold FLGT as of Q3 2023.

HighTower Advisors reported no remaining Fulgent Genetics position as of Q3 2023 after selling out during the quarter.
HighTower Advisors sold 5,784 Fulgent Genetics shares in Q3 2023, an estimated $213K.
HighTower Advisors first reported a position in Fulgent Genetics in Q4 2020 and held it in 10 quarters.
HighTower Advisors's Fulgent Genetics position peaked at $770K in Q4 2021.
201 funds tracked by Wall St. Rank held Fulgent Genetics as of Q3 2023.

Based on HighTower Advisors's 13F filing for Q3 2023, filed 8 Nov 2023.